Entering text into the input field will update the search result below

Arrowhead Pharmaceuticals' (ARWR) CEO Christopher Anzalone on Q2 2021 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2021 Earnings Conference Call May 4, 0000 6:00 PM ET

Company Participants

Vincent Anzalone – Vice President-Investor Relations

Christopher Anzalone – President and Chief Executive Officer

Javier San Martin – Chief Medical Officer

Ken Myszkowski – Chief Financial Officer

James Hassard – Chief Commercial Officer

Conference Call Participants

Maury Raycroft – Jefferies

Alethia Young – Cantor

Esther Rajavelu – UBS

Ted Tenthoff – Piper Sandler

Luca Issi – RBC Capital Markets

Patrick Trucchio – H.C. Wainwright

Sonia Gupta – Goldman Sachs

Keay Nakae – Charda

Mayank Mamtani – B. Riley Securities

Mani Foroohar – SVB Leerink


Ladies and gentlemen welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today’s recorded presentation all participants will be in a listen-only mode. After the presentation, there will be an opportunity to ask questions.

I will now hand the conference call over to Vincent Anzalone, Vice President of Investor

Relations for Arrowhead. Please go ahead Vince.

Vincent Anzalone

Thank you, Jessi. Good afternoon everyone. Thank you for joining us today to discuss Arrowhead’s results for its fiscal 2021 second quarter ended March 31, 2021. With us today from management are President and CEO, Dr. Christopher Anzalone, who will provide an overview of the quarter; Dr. Javier San Martin, our Chief Medical Officer, who will provide an update on our pipeline; and Ken Myszkowski, our Chief Financial Officer, who will give a review of the financials. In addition, James Hassard, our Chief Commercial Officer, and Dr. James Hamilton, our Senior Vice President of Discovery and Translational Medicine, will be available during the Q&A session of today’s call.

Before we begin, I would like to remind you that comments made during today’s call contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E

Recommended For You

Comments (2)

Z.TiSlMo profile picture
Arrowhead will save lots of lives in the next decades. Truly impressive!
Building an empire and WS is asleep... not long until ARWR captures the RNAI spotlight this summer and is shown as the clear leader in the space.
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About ARWR

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on ARWR

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.